IN THE MAZE OF MULTIPLE MYELOMA ,
BCMA-DIRECTED BsAbs MAY PROVIDE
A NEW WAY
FORWARD 1 , 2
B-cell maturation antigen ( BCMA ) is overexpressed on multiple myeloma ( MM ) cells 1 , 3
Bispecifi c antibodies ( BsAbs ) designed to target BCMA have the potential to function as tumor-recognizing immune enhancers and may offer a new way forward for MM patients 1-6
Keep seeking a new MMwayforward . com
References : 1 . Caraccio C , Krishna S , Phillips DJ , Schürch CM . Bispecifi c antibodies for multiple myeloma : a review of targets , drugs , clinical trials , and future directions . Front Immunol . 2020 ; 11:501 . doi : 10.3389 / fi mmu . 2020.00501 2 . Nadeem O , Tai YT , Anderson KC . Immunotherapeutic and targeted approaches in multiple myeloma . Immunotargets Ther . 2020 ; 9:201-215 . doi : 10.2147 / ITT . S240886 3 . Shah N , Chari A , Scott E , Mezzi K , Usmani SZ . B-cell maturation antigen ( BCMA ) in multiple myeloma : rationale for targeting and current therapeutic approaches . Leukemia . 2020 ; 34:985-1005 . doi . org / 10.1038 / s41375-020-0734-z 4 . Zhou X , Einsele H , Danhof S . Bispecifi c antibodies : a new era of treatment for multiple myeloma . J Clin Med . 2020 ; 9:1-14 . doi : 10.3390 / jcm9072166 5 . Swann JB , Smyth MJ . Immune surveillance of tumors . J Clin Invest . 2007 ; 117:1137-1146 . doi : 10.1172 / JCI31405 6 . Pratt G , Goodyear O , Moss P . Immunodefi ciency and immunotherapy in multiple myeloma . Br J Haematol . 2007 ; 138:563-579 . doi : 10.1111 / j . 1365-2141.2007.06705 . x
PP-E1A-USA-0042 © 2021 Pfi zer Inc . All rights reserved . September 2021